Eaton’s Vehicle Group Secures U.S. Department of Energy Grant to Develop Emissions-reducing Technologies for the Agricultural Sector
16.12.2021 21:15:00 EET | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has secured a $2.4 million grant from the U.S. Department of Energy (DOE) to develop new technologies to reduce emissions from agricultural equipment. This grant will accelerate Eaton’s progress in achieving its 2030 Sustainability Targets. By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005939/en/
Eaton’s variable valve actuation technologies are an ideal solution for reducing emissions produced by agricultural implements. (Photo: Business Wire)
Under the grant, Eaton plans to develop technologies that simultaneously reduce greenhouse gas (GHG) by 10% and nitrogen oxides (NOx) by 90% for agricultural powertrains designed for multiple-duty cycles. The technologies are required to span application diversity in the segment while being both cost-efficient and robust. Separately, Eaton also received a $4.9 million grant to develop a new compact and modular solid-state transformer to reduce the cost and size of DC fast-charging systems.
“Off-highway sector emissions levels, including in the agricultural segment, significantly lag behind on-road applications due to a lack of technology solutions,” said Dr. Mihai Dorobantu, director, Technology Planning and Government Affairs, Eaton’s Vehicle Group. “This grant could enable significant reductions in both GHG and NOx emissions that would then drive the technology and its benefits nationwide and help us meet our corporate sustainability objectives. The DOE funding supports our ongoing work to develop technologies that reduce emissions in applications that are difficult to decarbonize. The funding also enables research partnerships to optimize architectures and components.”
To achieve the grant’s objective, Eaton’s Vehicle Group will develop new components for agricultural applications and will modify existing technologies developed for commercial vehicles, including engine and aftertreatment systems. Agricultural solutions differ from advanced on-road technologies because they are used in unique and varying operating cycles.
An expansive portfolio of technologies will be leveraged to achieve target goals
By partnering with leading engine manufacturers, Eaton plans to achieve the DOE targets through innovative technologies that provide higher engine compression ratios, reduce friction and increase turbo machinery efficiency while minimizing mechanical losses.
Eaton will adapt its line of variable-valve actuation (VVA) solutions, originally designed for commercial vehicles, for agricultural use. Eaton’s VVA technologies are based on two building blocks — a rocker with a switchable capsule, and a split rocker for full deactivation. By combining these two building blocks, several VVA strategies can be utilized in virtually any engine architecture — from single and dual overhead cam to cam-in-designs, for engine displacements ranging from 2.0 to 15.0 liters.
Cylinder deactivation (CDA) is a VVA technology that consists of deactivating the intake and exhaust valve opening, as well as the fuel injection on some of the cylinders when the engine is running at low load. CDA is an ideal solution for commercial vehicles that make frequent stops, as well as many agricultural implements. CDA can reduce NOx emissions by up to 40% and carbon dioxide (CO2) by 5%-8%.
Eaton will also focus on active catalyst heating technology to assist with exhaust thermal management as part of achieving the DOE’s targets. Active heating solutions provide heat directly to the vehicle’s aftertreatment system, reducing harmful NOx emissions by warming the selective catalytic reduction (SCR) catalyst to approximately 200-250 degrees Celsius as quickly as possible, and maintaining this temperature during periods of low-load operation.
Additionally, Eaton plans to leverage its positive-displacement TVS® exhaust gas recirculation (EGR) pump to meet the program’s objectives. The EGR pump complements a high-efficiency turbocharger to reduce engine pumping losses, thereby increasing fuel economy and lowering emissions. Because the pump is a positive-displacement device, the engine controller uses the pump speed signal, as well as other Controller Area Network (CAN) sensor data, to accurately calculate EGR mass flow rate.
“This program is foundational to creating two market drivers in the off-highway segment —upcoming regulations to lower GHG and NOx emissions across the segment, and a significant economic benefit generated for end users,” Dorobantu said.
The DOE DC fast-charging grant aims to significantly reduce the time it takes to install charging infrastructures at end-user facilities. Eaton’s new technology will feature advanced components and an innovative cooling approach, eliminating the need for multiple power conversion devices. The goal is to reduce charging infrastructure barriers to commercial electric vehicle deployment by minimizing the need for facility modifications and allowing for charging installations in remote areas. The grant aligns with the DOE’s commitment to have zero-emission vehicles make up half of all vehicles sold in America by 2030 and achieve net-zero emissions economywide by 2050.
The grant also supports Eaton’s Vehicle Group and eMobility business's mission to produce sustainable solutions that enhance vehicle efficiency, safety and performance. Our Vehicle products include emission control components, engine valves, valvetrain systems, superchargers, transmissions, clutches and torque management systems. Our eMobility portfolio includes intelligent power electronics, reliable power distribution and protection solutions, and efficient power systems for electrified vehicles.
Learn more about Eaton’s Vehicle Group and eMobility businesses.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005939/en/
Contact information
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
